Prof Kanta Subbarao
Honorary (Professorial Fellow)
Department of Microbiology and Immunology
433 Scholarly works
68 Projects
HIGHLIGHTS
2026
Journal article
Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59
DOI: 10.1038/s41541-025-01355-y2026
Journal article
Influenza vaccine responses differ between young children previously exposed to influenza antigens via infection versus vaccination
DOI: 10.1038/s43856-026-01610-w2026
Journal article
Innovation, development, and licensure of improved influenza vaccines: the way forward
DOI: 10.1016/j.vaccine.2026.1291352026
Journal article
Corrigendum to “The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose” [J Infect 90 (2025)/106447]
DOI: 10.1016/j.jinf.2026.1068502026
Research grants (ARC, NHMRC, MRFF)
Transforming Knowledge on Long-Term Protective Immunity by mRNA and Protein Vaccines
2024
Research grants (international)
(CRA With Melbourne Health and Aus Bio) Development of a Novel Long Acting Pan-Influenza Antiviral Drug
2021
Research grants (ARC, NHMRC, MRFF)
Chimeric Next Generation COVID Vaccines
RECENT SCHOLARLY WORKS
2026
Journal article
Corrigendum to ‘Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia’ [J Infect 92 (2026)/106727]
DOI: 10.1016/j.jinf.2026.1068512026
Journal article
Reconciliation of titer differences between SARS-CoV-2 neutralizing antibody assays
DOI: 10.1128/jvi.00823-262026
Journal article
The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults.
DOI: 10.1016/j.vaccine.2026.1290342026
Journal article
ThePlatform trialInCOVID-19 priming andBOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults
DOI: 10.1016/j.vaccine.2026.1289702026
Journal article
Epistasis facilitates the long-term antigenic evolution of the influenza B virus hemagglutinin.
DOI: 10.64898/2026.07.22.7399942026
Journal article
Delivery of monoclonal antibodies using mRNA lipid nanoparticles confers protection against SARS-CoV-2 and influenza
DOI: 10.1016/j.omtn.2026.102873
RECENT PROJECTS
2024
Research contracts (non-grants)
Leyden SARS2/NL63 Block Contract - Assessment of the Antiviral Agents Against SARS-CoV-2 and Human Coronavirus NL63
2025
Research grants (other domestic)
Developing CRISPR Cas13 Antiviral Therapeutics for Respiratory Pathogens of Pandemic Potential